| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c22c6d06e5563aee18cc3c610cfa6180 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate |
2006-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67477d919b43a4d5995d30a8960bc8e0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4918547dd269cb7e7d266b8a63181b4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_556d79e0b0df7e9e59070c8d464eb3c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a39c0ddcd7c24da268f7ebd1ecab172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8cf5b0a271651e6fe7f60e0b7fd24da8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae43b9f3e6ea2cb033c50e0dad3396aa |
| publicationDate |
2007-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2635342-A1 |
| titleOfInvention |
Cytoprotective pharmaceutical combination which can be used in the prevention and treatment of systemic inflammatory response syndrome |
| abstract |
The invention relates to a pharmacological combination of a protein with cytoprotective properties and an immunomodulatory peptide. The peptide of the pharmacological combination is the linear LALF31-52 peptide which increases immunological defence mechanisms without inducing an exacerbated inflammatory response. The protein of the pharmacological combination is the epidermal growth factor which has a cytoprotective effect and which activates the signal transduction of cell survival genes. The inventive pharmacological combination confers resistance on the systemic immunocompetent cells in order to withstand damage caused by inflammatory cytokines and by bacterial endotoxins without activating molecular apoptosis pathways. In addition, the pharmacological combination alleviates the inflammatory events of the first stage of sepsis and of the inflammatory response against sterile traumatisms, thereby defending the organism against the invasion of pathogens or against inflammation mediators, without the inflammatory response being deleterious to the integrity thereof. |
| priorityDate |
2005-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |